ATE401314T1 - Benzodiazepin-derivate als gamma-secretase inhibitoren - Google Patents
Benzodiazepin-derivate als gamma-secretase inhibitorenInfo
- Publication number
- ATE401314T1 ATE401314T1 AT01972352T AT01972352T ATE401314T1 AT E401314 T1 ATE401314 T1 AT E401314T1 AT 01972352 T AT01972352 T AT 01972352T AT 01972352 T AT01972352 T AT 01972352T AT E401314 T1 ATE401314 T1 AT E401314T1
- Authority
- AT
- Austria
- Prior art keywords
- gamma
- secretase inhibitors
- benzodiazepine derivatives
- compounds
- benzodiazepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0025173.6A GB0025173D0 (en) | 2000-10-13 | 2000-10-13 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE401314T1 true ATE401314T1 (de) | 2008-08-15 |
Family
ID=9901256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01972352T ATE401314T1 (de) | 2000-10-13 | 2001-10-08 | Benzodiazepin-derivate als gamma-secretase inhibitoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6995155B2 (de) |
| EP (1) | EP1326849B1 (de) |
| JP (1) | JP2004511474A (de) |
| AT (1) | ATE401314T1 (de) |
| AU (1) | AU2001292126A1 (de) |
| CA (1) | CA2424812A1 (de) |
| DE (1) | DE60134874D1 (de) |
| GB (1) | GB0025173D0 (de) |
| WO (1) | WO2002030912A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001125908A (ja) * | 1999-10-26 | 2001-05-11 | Sony Corp | 入力装置および方法 |
| GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
| AU8800801A (en) * | 2000-09-08 | 2002-03-22 | James E Coleman | Surgical staple |
| US7060698B2 (en) * | 2003-05-19 | 2006-06-13 | Hoffmann-La Roche Inc. | Benzoxazepinone derivatives |
| US20070293482A1 (en) * | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
| US20060084672A1 (en) * | 2004-10-20 | 2006-04-20 | The Hospital For Sick Children | Method for modification of y-secretase activity through inhibition of Fkbp13 |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| US8133857B2 (en) | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| JP2010518064A (ja) | 2007-02-12 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Ａｄおよび関連状態の治療のためのピペラジン誘導体 |
| KR101595238B1 (ko) | 2007-12-21 | 2016-02-18 | 리간드 파마슈티칼스 인코포레이티드 | 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도 |
| EP2291181B9 (de) | 2008-04-18 | 2013-09-11 | University College Dublin National University Of Ireland, Dublin | Captodiamine zur Behandlung von depressionartigen Symptomen |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| WO2011009064A1 (en) * | 2009-07-17 | 2011-01-20 | The J. David Gladstone Institutes | Methods of controlling cell proliferation |
| BR112012008849A2 (pt) | 2009-10-14 | 2015-09-22 | Schering Corp | composto, composição farmacêutica, e, uso de um composto |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| EP2601293B1 (de) | 2010-08-02 | 2017-12-06 | Sirna Therapeutics, Inc. | Rna-interferenz-vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina) |
| KR102413007B1 (ko) | 2010-08-17 | 2022-06-24 | 시르나 쎄러퓨틱스 인코퍼레이티드 | 짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제 |
| US8946216B2 (en) | 2010-09-01 | 2015-02-03 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as ERK inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
| EP2654748B1 (de) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Indazolderivate als erk-hemmer |
| US9629891B2 (en) | 2011-10-17 | 2017-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
| EP2770987B1 (de) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Neue verbindungen als erk-hemmer |
| EP3358013B1 (de) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| EP2900241B1 (de) | 2012-09-28 | 2018-08-08 | Merck Sharp & Dohme Corp. | Neuartige verbindungen als erk-hemmer |
| WO2014085216A1 (en) | 2012-11-28 | 2014-06-05 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| KR102196882B1 (ko) | 2012-12-20 | 2020-12-30 | 머크 샤프 앤드 돔 코포레이션 | Hdm2 억제제로서의 치환된 이미다조피리딘 |
| AU2013366668B2 (en) | 2012-12-20 | 2017-07-20 | Janssen Pharmaceutica Nv | Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators |
| JP6283691B2 (ja) | 2013-01-17 | 2018-02-21 | ヤンセン ファーマシューティカ エヌ．ベー． | γセクレターゼ調節剤としての新規な置換ピリド−ピペラジノン誘導体 |
| US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
| EP3094323A4 (de) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Verfahren und zusammensetzungen zur modulierung von hormonspiegeln |
| EP3525785A4 (de) | 2016-10-12 | 2020-03-25 | Merck Sharp & Dohme Corp. | Kdm5-inhibitoren |
| WO2019094311A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2019222298A1 (en) * | 2018-05-15 | 2019-11-21 | Bristol-Myers Squibb Company | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof |
| EP3823672A1 (de) | 2018-07-19 | 2021-05-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Kombinationen zur behandlung von krebs |
| KR20210046009A (ko) | 2018-08-07 | 2021-04-27 | 머크 샤프 앤드 돔 코포레이션 | Prmt5 억제제 |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| US11993602B2 (en) | 2018-08-07 | 2024-05-28 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
| NZ788874A (en) | 2019-12-17 | 2024-08-30 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| US20230416830A1 (en) | 2020-11-16 | 2023-12-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
| US20240116945A1 (en) | 2022-09-02 | 2024-04-11 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
| TW202432099A (zh) | 2022-10-25 | 2024-08-16 | 美商默沙東有限責任公司 | 源自依克沙替康(exatecan)之adc連接子-載藥(payload)、醫藥組合物及其用途 |
| WO2024129628A1 (en) | 2022-12-14 | 2024-06-20 | Merck Sharp & Dohme Llc | Auristatin linker-payloads, pharmaceutical compositions, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5426185A (en) | 1993-11-22 | 1995-06-20 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
| HRP970705A2 (en) | 1996-12-23 | 1998-10-31 | Warren J. Porter | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
| FR2782997A1 (fr) | 1998-09-08 | 2000-03-10 | Hoechst Marion Roussel Inc | Nouveaux derives de la benzodiazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicaments et compositions pharmaceutiques les renfermant |
| CN1636011A (zh) | 1998-12-24 | 2005-07-06 | 杜邦药品公司 | 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬 |
| GB0012671D0 (en) * | 2000-05-24 | 2000-07-19 | Merck Sharp & Dohme | Therapeutic agents |
-
2000
- 2000-10-13 GB GBGB0025173.6A patent/GB0025173D0/en not_active Ceased
-
2001
- 2001-08-08 US US10/399,231 patent/US6995155B2/en not_active Expired - Fee Related
- 2001-10-08 DE DE60134874T patent/DE60134874D1/de not_active Expired - Fee Related
- 2001-10-08 JP JP2002534298A patent/JP2004511474A/ja not_active Withdrawn
- 2001-10-08 WO PCT/GB2001/004474 patent/WO2002030912A1/en active IP Right Grant
- 2001-10-08 EP EP01972352A patent/EP1326849B1/de not_active Expired - Lifetime
- 2001-10-08 CA CA002424812A patent/CA2424812A1/en not_active Abandoned
- 2001-10-08 AU AU2001292126A patent/AU2001292126A1/en not_active Abandoned
- 2001-10-08 AT AT01972352T patent/ATE401314T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1326849A1 (de) | 2003-07-16 |
| JP2004511474A (ja) | 2004-04-15 |
| WO2002030912A1 (en) | 2002-04-18 |
| EP1326849B1 (de) | 2008-07-16 |
| US20040024203A1 (en) | 2004-02-05 |
| AU2001292126A1 (en) | 2002-04-22 |
| GB0025173D0 (en) | 2000-11-29 |
| CA2424812A1 (en) | 2002-04-18 |
| DE60134874D1 (de) | 2008-08-28 |
| US6995155B2 (en) | 2006-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| ATE386028T1 (de) | Zyklohexylsulfone als gamma-sekretase-inhibitoren | |
| DE60112957D1 (de) | Sulfamide als gamma-secretase-inhibitoren | |
| ATE346039T1 (de) | Sulfonamido-substituierte verbrückte bicycloalkylderivative | |
| ATE464287T1 (de) | Cyclohexyl-sulphone als gamma-sekretase- inhibitoren | |
| ATE368031T1 (de) | Neue gamma secretase inhibitoren | |
| DE60312017D1 (de) | Sulfonderivate zur hemmung von gamma-secretase | |
| ATE355278T1 (de) | Isochinolinon derivate als parp inhibitoren | |
| GB0225475D0 (en) | Therapeutic agents | |
| DE60121461D1 (de) | Kondensierte pyridoindolderivate | |
| ATE300543T1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| DE60115466D1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| ATE365735T1 (de) | Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel | |
| TR200201128T2 (tr) | PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri. | |
| DE60112960D1 (de) | Kondensierte pyridoindolderivate | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| DE60122559D1 (de) | Indolderivate als pde5-inhibitoren | |
| NZ516620A (en) | 1,4-substituted 4,4-diaryl cyclohexanes | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| TR200100475T2 (tr) | N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları. | |
| GB0522908D0 (en) | Therapeutic agents | |
| SE9902596D0 (sv) | Pharmaceutically active compounds | |
| ATE388710T1 (de) | Phthalazinderivate als phosphodiesterase-4-hemmer | |
| DE60119949D1 (de) | 1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE ANWENDUNG IN DER BEHANDLUNG VON SCHMERZEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |